Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Praxis Precision Medicines Stock Performance

PRAX stock opened at $239.02 on Thursday. The stock has a market capitalization of $6.67 billion, a PE ratio of -18.49 and a beta of 2.79. The company has a fifty day moving average of $326.50 and a 200-day moving average of $319.14. Praxis Precision Medicines, Inc. has a one year low of $52.62 and a one year high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.67) by $0.80. Equities analysts forecast that Praxis Precision Medicines, Inc. will post -13.90 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRAX. Avior Wealth Management LLC acquired a new stake in shares of Praxis Precision Medicines during the third quarter valued at $227,000. GAMMA Investing LLC lifted its stake in shares of Praxis Precision Medicines by 30.1% during the third quarter. GAMMA Investing LLC now owns 432 shares of the company’s stock valued at $126,000 after buying an additional 100 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Praxis Precision Medicines in the 2nd quarter worth approximately $38,000. Nykredit A S acquired a new position in Praxis Precision Medicines in the 2nd quarter valued at $261,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Praxis Precision Medicines during the 2nd quarter worth $2,698,000. Institutional investors and hedge funds own 67.84% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. BTIG Research raised their target price on Praxis Precision Medicines from $810.00 to $826.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a research report on Monday, August 24th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Needham & Company LLC reiterated a “buy” rating and issued a $582.00 price target on shares of Praxis Precision Medicines in a report on Thursday, September 24th. Finally, Wall Street Zen upgraded shares of Praxis Precision Medicines from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $610.95.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.

Praxis’ pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions.